Skip to main
BCAX
BCAX logo

BCAX Stock Forecast & Price Target

BCAX Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Bicara Therapeutics Inc. is positioned favorably within the biopharmaceutical sector due to its innovative bifunctional therapy, ficerafusp alfa, which exhibits a promising overall response rate (ORR) that significantly outperforms current standard treatments such as Keytruda. The therapy, in combination with Keytruda, has demonstrated a median progression-free survival (mPFS) of 9.9 months and a median overall survival (mOS) of 21.3 months, indicating a strong survival benefit compared to existing therapies. Furthermore, clinical data suggests that this combination may provide a more effective treatment option for patients with solid tumors, reinforcing a positive outlook for the company's stock.

Bears say

Bicara Therapeutics Inc. reported a net loss of $0.50 per share for 2Q25, consistent with prior estimates, indicating a challenging financial performance as the company continues to navigate clinical development. Numerous risks were outlined, including the potential for negative clinical results with its primary asset, ficerafusp alfa, and possible delays in advancing this treatment into registrational trials, which could hinder future growth. Additionally, the projected full-year 2025 net loss of $2.27 per share suggests ongoing financial instability and the risk of dilution may further impact investor confidence and stock performance.

BCAX has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicara Therapeutics Inc (BCAX) Forecast

Analysts have given BCAX a Buy based on their latest research and market trends.

According to 5 analysts, BCAX has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicara Therapeutics Inc (BCAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.